Bone marrow SELENOP+ macrophages support hematopoiesis after transplantation via GAS6-AXL signaling pathway
Cancer Letters · 2026-06 · 647 · 218441
DOI: 10.1016/j.canlet.2026.218441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-06. Verfasst von Meng-Zhu Shen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Intercellular Signaling Peptides and Proteins, Proto-Oncogene Proteins, Receptor Protein-Tyrosine Kinases, Macrophages. Die Arbeit nennt 70 Literaturangaben. Gefördert von: Peking University Health Science Center, Peking University, National Key Research and Development Program of China.
Abstract (Originalsprache)
Poor hematopoietic reconstitution (PHR), a serious complication after chemotherapy or radiotherapy in patients with hematological or solid malignancies, which lacks effective treatment options because its underlying pathogenesis remains unclear. Bone marrow macrophages (BM MΦs) are multifunctional, plastic cells essential in hematopoiesis though our previous study demonstrated distinct hematopoietic regulatory role between M1 and M2 subtypes. However, the specific phenotype of M2-MΦ and pathways involved in hematopoietic support remain unclear. Here, we identified a novel population of BM-MΦs, SELENOP+ MΦs, that exhibit an M2-biased phenotype with hematopoietic stem cell (HSC)-supporting ability. These cells were markedly impaired in patients with poor graft function (PGF) after allogeneic HSC transplantation, potentially because of defective autocrine GAS6-AXL (ligand-receptor) signaling. Both in vitro and BM MΦ-specific AXL knockdown mouse models confirmed that reduced AXL activity contributed to MΦ dysfunction and the downstream reduction in IGF1 secretion. Notably, treatment with GAS6 partially restored the HSC-supporting ability of impaired BM MΦ from PGF patients in vitro. Overall, our study identified an HSC-supportive SELENOP+ MΦ subset regulated by GAS6-AXL signaling, offering novel therapeutic insights for impaired hematopoiesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Co…
- Chief Department of Hematology, The Fifth Medical Center, PLA General Hospital, Beijing, China.
Förderung
- Peking University Health Science Center
- Peking University
- National Key Research and Development Program of China
- Beijing Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Shen, M. Z., Guo, L. P., Mo, X. D., Yu, Y. T., Li, C. Y., Chen, D. D., Lyu, Z. S., Zhao, H. Y., Wen, Q., Zhang, Y. Y., Xu, L. P., Wang, Y., Zhang, X. H., Liu, D. H., Huang, X. J., & Kong, Y. (2026). Bone marrow SELENOP+ macrophages support hematopoiesis after transplantation via GAS6-AXL signaling pathway. Cancer Letters, 647, 218441. https://doi.org/10.1016/j.canlet.2026.218441
Vancouver
Shen MZ, Guo LP, Mo XD, Yu YT, Li CY, Chen DD, et al. Bone marrow SELENOP+ macrophages support hematopoiesis after transplantation via GAS6-AXL signaling pathway. Cancer Letters. 2026;647:218441. doi:10.1016/j.canlet.2026.218441
BibTeX
@article{Shen2026,
author = {Shen, Meng-Zhu and Guo, Li-Ping and Mo, Xiao-Dong and Yu, Ya-Ting and Li, Chen-Yuan and Chen, Dan-Dan and Lyu, Zhong-Shi and Zhao, Hong-Yan and Wen, Qi and Zhang, Yuan-Yuan and Xu, Lan-Ping and Wang, Yu and Zhang, Xiao-Hui and Liu, Dai-Hong and Huang, Xiao-Jun and Kong, Yuan},
title = {Bone marrow SELENOP+ macrophages support hematopoiesis after transplantation via GAS6-AXL signaling pathway},
journal = {Cancer Letters},
year = {2026},
volume = {647},
pages = {218441},
doi = {10.1016/j.canlet.2026.218441}
}
EUVIMED